SEGRO plc ("the Company")
Director Shareholdings
8 April 2009
In accordance with the Directors' intentions stated in the Prospectus sent to
shareholders on 4 March 2009, each Director took up their rights to subscribe
in full for New Ordinary Shares under the Rights Issue.
Following the rights issue, the interests of the Directors in the Company's
ordinary 1p shares are as follow:
Director Number of New Ordinary 1p Resulting Total Holding of
Shares acquired under the Ordinary 1p Shares
Rights Issue
Nigel Rich 783,240 848,510
Ian Coull 2,507,724 2,716,701
David Sleath 537,336 582,114
Lord Blackwell 69,684 125,491
Stephen Howard 83,076 89,999
Lesley MacDonagh 60,000 65,000
Andrew Palmer 44,304 47,996
Christopher Peacock 95,644 103,636
Thom Wernink 111,864 121,186
The holdings shown above supersede those set out on page 106 of the Prospectus.
Interests in the Company's share schemes will be adjusted in accordance with
the rules of each scheme to reflect the effects of the Rights Issue and these
adjustments will be announced in due course.
Robin Healy
Assistant Company Secretary
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.